Predictive significance of thyroid transcription factor-1 expression in patients with non‑squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib
- Authors:
- Yoshiro Nakahara
- Yukio Hosomi
- Makoto Saito
- Masumi Ogawa
- Tsunekazu Hishima
- Tatsuru Okamura
- Jiichiro Sasaki
- Noriyuki Masuda
- Published online on: April 21, 2016 https://doi.org/10.3892/mco.2016.870
- Pages: 14-18
Metrics:
Total Views:
0
(Spandidos Publications:
| PMC Statistics:
)
Total PDF Downloads:
0
(Spandidos Publications:
| PMC Statistics:
)
Abstract
Little is known on the efficacy of erlotinib treatment in patients expressing wild-type epidermal growth factor receptor (EGFR). This study is a retrospective review of patients with non‑squamous, non‑small‑cell lung cancer (NS‑NSCLC) and wild‑type EGFR who were treated with erlotinib alone as second- or later‑line chemotherapy at the Tokyo Metropolitan Cancer and Infectious Diseases Center of Komagome Hospital (Tokyo, Japan) between December, 2008 and December, 2013. Thyroid transcription factor‑1 (TTF-1) was immunohistochemically analyzed in 26 of 53 patients, among whom 20 (77%) and 6 (23%) were considered as TTF‑1‑positive and -negative, respectively. The median follow‑up of these 26 patients was 133 days (range, 26‑873 days). The time‑to‑treatment failure was significantly longer in TTF‑1‑positive compared with that in TTF‑1‑negative patients [49.5 vs. 20.0 days; 95% confidence interval (CI): 28‑90 vs. 14‑74 days, respectively; P=0.01]. The overall survival was significantly better for TTF‑1‑positive (227 days; 95% CI: 110‑366 days) compared with TTF-1-negative patients (P=0.0002). Therefore, the expression of TTF-1 may serve as a useful tool for predicting the efficacy of erlotinib in patients with NS-NSCLC expressing wild‑type EGFR.
